SNDX News and Press, Syndax Pharmaceuticals Inc. From 03/01/22

The clinical-stage biotech, Syndax Pharmaceuticals (NASDAQ:SNDX), announced on Tuesday that Kate Madigan, M.D., will be appointed as the company’s new Chief Medical Officer, effective immediately. She will replace Michael Meyers, who will remain with the company until June before takin...

Syndax Pharmaceuticals press release (NASDAQ:SNDX): Q4 GAAP EPS of $1.81 beats by $1.84. Revenue of $126.6M (+63200.0% Y/Y) beats by $67.92M. For further details see: Syndax Pharmaceuticals GAAP EPS of $1.81 beats by $1.84, revenue of $126.6M beats by $67.92M

Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update - Enrollment remains on track for pivotal programs of SNDX-5613 and axatilimab; topline data expected starting in 1H23 - - Initiation of three new trials of SNDX-56...

Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer PR Newswire WALTHAM, Mass. , March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmac...

Soligenix to Present at the 2022 BIO CEO & Investor Conference Soligenix to Present at the 2022 BIO CEO & Investor Conference PR Newswire PRINCETON, N.J. , Feb. 8, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a ...

Syndax Pharmaceuticals (NASDAQ:SNDX) said Michael Metzger, president and COO, will transition to the role of CEO, effective Feb. 3. Briggs Morrison, CEO, will transition to the role of president, head of R&D. Metzger and Morrison will remain on SNDX's board. "With topline data expected ea...

Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; B...

AAP, ACTG, AESE, OTCPK:AOIFF, DADAASTS, ATHX, AXON, AYTU, BIOC, BITF, CIDM, CMP, OTCQX:CWBHF, CWBR, CWCO, CYBN, DM, DNMR, DRIO, OTCQB:ELTP, ETON, EVFM, GLAD, GNLN, GOEV, IBIO, IDEX, INPX, IONQ, ISUN, LCID, LUNA, MARK, OTCQX:MRMD, MVST, NDRA, NEPT, PLBY, POWW, PRCH, PRPO, QFIN, RKDA,...

Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference PR Newswire WALTHAM, Mass. , Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company dev...

Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference PR Newswire WALTHAM, Mass. , Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company...